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was excellent with a mean of 96.1% (range 95.2%-100%) of pills con-
sumed over the 12-week treatment.
The results of this study add to the existing new evidence of the
efficacy of DAAs in patients with inherited blood disorders including
thalassemia. Table 1 summarizes the studies treating HCV in thalasse-
mia patients using DAAs.1,4–8 Importantly, the efficacy of these DAA
regimens is not impacted by iron overload and is further supported
by the high safety profile and lack of evidence of any significant
drug–drug interaction. Early treatment of chronic HCV in patients
with blood disorders should be considered in attempt to reduce liver-
related morbidity and mortality.
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Macrocytosis, an elevated mean corpuscular volume (MCV) of eryth-
rocytes, is a highly prevalent phenomenon in adult individuals.1 MCV
is the measurement of the average volume of red blood cells, and
macrocytosis is defined as a MCV exceeding 100 fL. Currently, in text-
books and guidelines a myriad causes are being mentioned for macro-
cytosis, with vitamin B12 and folate deficiency, alcohol use, myeloid
dysplastic syndromes, and liver disease as the most prominent ones.2
In the 70s, a number of papers have reported a positive association
between smoking and MCV.3,4 This has nowadays, however, not
resulted in inclusion of cigarette smoking as an important cause of
macrocytosis in textbooks and guidelines. Hence, in the current study,
we aimed to investigate the association between smoking, assessed
by both questionnaire and 24-hour urinary cotinine excretion, as
objective measurement of nicotine exposure, with MCV in 2 large
population-based cohorts.
First, we analyzed data from the Lifelines cohort study. Lifelines is
a large multi-disciplinary prospective population-based cohort study
which examines, in a unique 3-generation design, the health and
health-related behaviors of persons living in the north of The Nether-
lands. For the present study, we included 131 886 of the 167 729
subjects (aged 18-93 years) of whom hematology indices, drinking
and smoking behavior were available. Second, we analyzed data from
the Prevention of Renal and Vascular End-Stage Disease (PREVEND)
study, a prospective, population-based cohort of Dutch men and
women aged 28-75 years. For current analyses, we used data from
the second survey (n = 6894) and excluded missing data on smoking
behavior (n = 86), resulting in 6808 participants eligible for analyses.
Smoking status was categorized as never, former, and current (<6,
6-20, or >20 cigarettes/d). To exclude possible misclassification or
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use
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under- or overestimation of number of cigarettes smoked per day as
determined by questionnaire, 24-hour urinary cotinine levels were
measured. Alcohol use was categorized as no alcohol use, 1 U of alco-
hol per month to 1 U/wk, >1 U/wk to 7 U of alcohol per week, >1
U/d to 3 U of alcohol per day, or > 3 U of alcohol per day. Details of
the Lifelines cohort and PREVEND study regarding clinical examina-
tion, biochemical measurements, data description and statistical ana-
lyses are described in the Supporting Information. Similarly, baseline
demographics and clinical characteristics of the included 131 886
community-dwelling participants and 6808 PREVEND participants are
shown in Supporting Information Tables S1 and S2.
Of the 131 886 Lifelines participants (age 45  13 years, 40%
males), 47% were nonsmokers, 33% were former smokers and 20%
were current smokers. Of the current smokers, 28% smoked <6 ciga-
rettes per day, 55% smoked 6-20 cigarettes per day and 18%
smoked > 20 cigarettes per day. Hemoglobin levels were higher in
current smokers (14.3  1.2 g/dL) compared with nonsmokers (14.0
 1.3 g/dL, P < .001). Similarly, MCV levels were higher in current
smokers (91.4  4.3 fL) compared with nonsmokers (89.2  4.0 fL,
P < .001, Figure 1A). Macrocytosis was present in 494 (1.9%) of cur-
rent smokers compared with 166 (0.3%) of nonsmokers (P < .001,
Figure 1B).
In univariable linear regression analysis, current smoking, compared
with nonsmoking, was positively associated with MCV (β = 0.24,
P < .001). In multivariable regression analysis, performed in the whole
cohort, current smoking compared with nonsmoking, remained posi-
tively associated with MCV (β = 0.23, P < .001), independent of adjust-
ment for age, sex, estimated glomerular filtration rate (eGFR), body
mass index (BMI), and alcohol use. Multivariable regression analysis was
also performed in a subgroup of participants from whom also gamma-
FIGURE 1 Association of smoking and 24-hour urinary cotinine excretion levels with mean corpuscular volume and macrocytosis. A, The
association between smoking status and MCV in the lifelines cohort. Reported P-values are shown in respect to reference category of
nonsmokers. B, The prevalence of macrocytosis for each smoking status in the lifelines cohort. Reported P-values are shown in respect to
reference category of nonsmokers. C, The association between smoking status and MCV in the PREVEND study. Reported P-values are shown in
respect to reference category of nonsmokers. D, The association between 24-hour urinary cotinine excretion levels and MCV by means of
restricted cubic splines. Three knots have been specified at the 10th, 50th, and 90th of 24-hour urinary cotinine percentiles. The 95% CIs are
indicated by the shaded areas. Twenty-four urinary cotinine levels have been natural log transformed. Abbreviations: MCV, mean corpuscular
volume; PREVEND, prevention of renal and vascular end-stage disease. *P < .05 **P < .01 ***P < .001
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glutamyltransferase (GGT), alanine aminotransferase (ALAT), free
thyroxine (FT4), and high-sensitivity C-reactive protein (hs-CRP) were
available (n = 36 109) with the same result (β = 0.23, P < .001).
Similarly, in logistic regression, smoking was a strong determinant of
macrocytosis (OR 6.25, 95% CI 5.2-7.51; P < .001 in the total cohort, OR
6.00, 95% CI 4.12-8.73; P < .001 in the subgroup of n = 36 109),
independent of adjustment for potential confounders.
Hereafter, we divided current smoking into categories of ciga-
rettes smoked per day. In multivariate analysis, all smoking categories
(<6 cigarettes [β = 0.07, P < .01], 6-20 cigarettes [β = 0.22, P < .001],
and >20 cigarettes [β = 0.19, P < .001]) were associated with MCV,
independent of adjustment for potential confounders. The association
remained the same after adjustment for GGT, ALAT, FT4, and hs-CRP
(<6 cigarettes [β = 0.06, P < .001), 6-20 cigarettes [β = 0.22, P < .001],
and >20 cigarettes (β = 0.21, P < .001]).
Of the 6808 subjects (age 53  12 years, 50% males) in the PRE-
VEND study, 29% were nonsmokers, 43% were former smokers, and
28% were current smokers. Of the latter, 16% smoked <6 cigarettes
per day, 70% smoked 6-20 cigarettes per day, and 14% smoked >20
cigarettes per day. Hemoglobin levels were higher in current smokers
(13.9  1.2 g/dL) compared with nonsmokers (13.6  1.3 g/dL,
P < .001). Similarly, MCV levels were higher in current smokers
(92.3  4.7 fL) compared with nonsmokers (89.2  4.3 fL, P < .001,
Figure 1C). Macrocytosis was present in 73 (4%) of current smokers
compared with 8 (0.4%) of nonsmokers (P < .001).
In univariable linear regression analysis, current smoking, com-
pared with nonsmoking, was positively associated with MCV
(β = 0.30, P < .001). In multivariable analysis, current smoking, com-
pared with nonsmoking, remained positively associated with MCV
(β = 0.24, P < .001), independent of adjustment for age, sex, eGFR,
BMI, hs-CRP, alcohol use, GGT, ALAT, FT4, vitamin B12, and folic acid.
Similarly, in logistic regression, smoking was a strong determinant of
macrocytosis (OR, 8.54, 95% CI 2.57-28.37; P < .001), independent of
adjustment for potential confounders.
Hereafter, we divided current smoking into categories of ciga-
rettes smoked per day. In multivariate analysis, smoking <6 cigarettes
(β = 0.03, P = .06), was not associated with MCV, whereas smoking
6-20 cigarettes (β = 0.24, P < .001), and smoking >20 cigarettes per
day (β = 0.13, P < .001) remained, compared with nonsmoking, associ-
ated with MCV, independent of adjustment for potential confounders.
As sensitivity analysis, we repeated in the PREVEND study the
analysis with 24-hour urinary cotinine excretion levels as objective
reflection of smoking. Twenty-four hour urinary cotinine excretion
was strongly correlated with current smoking (β = 0.82, P < .001). Sim-
ilar to the primary analysis, we identified a strong positive association
between 24-hour urinary cotinine excretion and MCV (β = 0.26,
P < .001, Figure 1D). The association remained independent of adjust-
ment for potential confounders (β = 0.23, P < .001).
In this study, we have shown that smoking, assessed both by
means of a self-administered questionnaire and by 24-hour urinary
cotinine excretion levels, was strongly positively associated with MCV.
Importantly, this association was independent of known causes of mac-
rocytosis, including alcohol use. A few years ago, McNamee et al.5 and
O’Reilly et al.6 reinvestigated the association between smoking as
unrecognized cause of macrocytosis and showed that cigarette smoking
was a significant risk factor for macrocytosis, independent of other
known causes. Unfortunately, at present cigarette smoking is still not
mentioned in textbooks and major guidelines, and clinicians are gener-
ally unaware of this association. The major drawback of the previously
performed studies was that smoking status was assessed by means of a
self-administered questionnaire, which might still be regarded as a sub-
jective measurement of smoking status. In this study, we underline the
importance of this association, and we are the first to utilize an objec-
tive measurement that is, urinary cotinine excretion levels, for the cur-
rent association. The latter combined with the large patient populations
can be regarded also as the major strength of this study. Due to the
observational design of this study, we cannot discern potential mecha-
nisms for the strong association between smoking and MCV. Finally,
despite the extensive number of factors for which we adjust, residual
confounding can still not be excluded.
In conclusion, smoking is an important determinant of MCV levels
and macrocytosis, independent of prominent causes such as alcohol
intake, liver disease, vitamin B12, and folic acid deficiency. Smoking
should be included in current guidelines regarding known causes of an
elevated MCV, and the current study might draw more attention to
the mechanism by which smoking causes macrocytosis independent
of alcohol intake.
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Recurrent mutations in the isocitrate dehydrogenase gene (IDH) have
been identified in acute myeloid leukemia (AML), both in the cytosolic
IDH1 enzyme and in its mitochondrial homolog, IDH2.1 Approxi-
mately 15%-20% of AML patients have mutations in IDH1 or IDH2.2
Normal counterparts of these enzymes play their role in the citric acid
cycle, catalyzing the oxidative decarboxilation of isocitrate and pro-
ducing alpha-ketoglutarate; mutant IDH1 and IDH2 gain the activity
to convert the alpha-ketoglutarate into 2-hydroxyglutarate, an onco-
metabolite that leads to epigenetic changes that promote cellular
transformation through deregulation of mitochondrial function
increasing BCL-2 dependence (B-cell leukemia/lymphoma-2, an antia-
poptotic protein) in AML cells.1 A subtle approach to face a malig-
nancy with this molecular profile is to exploit the so called synthetic
lethality, a strategy based on the concept of nononcogene addiction,
wherein cells expressing an oncogenic mutation (ie, IDH1/2) exhibit
dependence on subsets of nononcogenes (ie, BCL-2) for survival.1
Venetoclax is a small and orally available molecule that target specifi-
cally the BH3 domain of BCL-2 (hence the name BH3 mimetic)
approved for the treatment of Chronic Lymphocytic Leukemia. Sev-
eral studies on the use of venetoclax as single agent in relapsed/
refractory AML (r/r AML) demonstrated clinical activity with tolerable
and safe profile3; furthermore the addition of venetoclax to decitabine
or azacitidine seems to sensitize AML cells to these hypomethylating
agents (HMAs), in particular for patients with IDH mutations.4–6
Relapsed AML after allogeneic hematopoietic stem cell transplan-
tation (HSCT) have poor prognosis despite numerous therapies
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